Evidence map›Paper›PMID 42725918›Full record

ArticleBriefings in bioinformatics2026

BOMIFA: biologically informed multi-omics integration with graph contrastive learning for cancer prognosis in women.

Zixiao Lu, Jiajun Wang, Yuping Liang, Zhenghao Lin, Yingyin Tan, Qian Ma, Wu Zhou, Yi Zhao, Siwen Xu

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zixiao LuSchool of Medical Information Engineering, Guangzhou University of Chinese Medicine, No. 232 Waihuan East Road, Panyu District, Guangzhou 510006, China.ORCID 0000-0003-0809-8703
Jiajun WangSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, No. 280 Waihuan East Road, Panyu District, Guangzhou 510006, China.
Yuping LiangSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, No. 280 Waihuan East Road, Panyu District, Guangzhou 510006, China.
Zhenghao LinSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, No. 280 Waihuan East Road, Panyu District, Guangzhou 510006, China.
Yingyin TanSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, No. 280 Waihuan East Road, Panyu District, Guangzhou 510006, China.
Qian MaSchool of Medical Information Engineering, Guangzhou University of Chinese Medicine, No. 232 Waihuan East Road, Panyu District, Guangzhou 510006, China.
Wu ZhouSchool of Medical Information Engineering, Guangzhou University of Chinese Medicine, No. 232 Waihuan East Road, Panyu District, Guangzhou 510006, China.
Yi ZhaoSchool of Medical Information Engineering, Guangzhou University of Chinese Medicine, No. 232 Waihuan East Road, Panyu District, Guangzhou 510006, China.ORCID 0000-0001-6046-8420
Siwen XuSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, No. 280 Waihuan East Road, Panyu District, Guangzhou 510006, China.ORCID 0000-0001-7936-0639

Funding

Guangdong Provincial Administration of Traditional Chinese Medicine TCM Research Projects 20261211Guangdong Provincial Medical Research Foundation A2024252National Natural Science Foundation of China 82203200
6 · The paper itself

Abstract

Accurate survival prediction remains a central challenge in precision oncology, particularly for female patients whose sex-specific molecular characteristics are often under-modeled in prior studies. Although multi-omics integration enables a deeper exploration of prognostic biomarkers, existing methods rely on mathematically driven fusion strategies, which tend to dilute omics-specific signals and fail to capture biological regulatory hierarchies across omics layers. To address these limitations, we propose BOMIFA (Biologically informed Omics representation and Multi-omics Integration Framework), a deep graph-based framework for survival prediction and biomarker discovery in female patients using DNA methylation, mRNA, and miRNA expression data. BOMIFA incorporates two key innovations. First, graph contrastive learning is leveraged within each omics encoder to enhance intra-omics representation learning and amplify prognostically relevant signals. Then, a biologically informed cross-omics attention mechanism is deployed to explicitly model directional regulatory dependencies, enabling inter-omics information exchange aligned with known molecular hierarchies. Extensive benchmarking on eight cancer cohorts demonstrates that BOMIFA consistently outperforms existing prognostic methods in female patients. Moreover, saliency map-based gradient attribution enables the identification of female-associated prognostic biomarkers that were overlooked in prior mixed-sex analyses.

Indexed as

Biomarkers, TumorComputational BiologyNeoplasmsDNA MethylationFemaleHumansMicroRNAsMultiomicsPrognosisBiomarkers, TumorMicroRNAscancer prognosiscross attentionfemalegraph contrastive learningmulti-omics

Identifiers

PMID42725918
PMCPMC13563673

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.